Stoke Therapeutics Inc
NASDAQ:STOK
Stoke Therapeutics Inc
NASDAQ:STOK
Price:
11.55 USD
0.61%
Market Closed
Updated:
May 14, 2024
Section:
Relative Value
The Relative Value of one
STOK
stock under the Base Case scenario is
7.07
USD.
Compared to the current market price of 11.55 USD,
Stoke Therapeutics Inc
is
Overvalued by 39%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
STOK
Relative Value
Base Case
7.07
USD
Overvaluation 39%
Valuation Multiples
Multiples Across Competitors
STOK Competitors Multiples
Stoke Therapeutics Inc Competitors
Stoke Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Stoke Therapeutics Inc
NASDAQ:STOK
|
602m USD | 76.7 | -5.5 | -3.6 | -3.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
284.8B USD | 5.2 | 59.1 | 12.8 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
165.5B USD | 5.6 | 44 | 18.6 | 30.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.8B USD | 11.2 | 30.6 | 24.7 | 25.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.7B USD | 8.2 | 27.9 | 22.6 | 25 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.2B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.2B USD | 3.1 | 173.9 | 7 | 9.2 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
48.1B USD | 9.3 | -8.1 | -8.8 | -7.8 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.8B USD | 3.4 | 28.1 | 14.3 | 17.9 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.5T KRW | 18.2 | 73.8 | 45.2 | 62.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
